Program
cp-547632
Also written as “PAN-90806 Ophthalmic Solution”, “CP-547,632” and “PAN-90806 Ophthalmic Suspension”.
Its studies are mostly in Macular Degeneration · Diabetic Retinopathy · Lung Neoplasms · Ovarian Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PanOptica | 30 open or running | phase 2since Mar 14, 2018 | Dec 20, 2013 | none ahead |
| Pfizer | 20 open or running | phase 2since Dec 22, 2003 | Dec 22, 2003 | none ahead |
| Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | 11 open or running | phase 1since Jun 22, 2026 | Jun 22, 2026 | Dec 30, 2026phase 1 · NCT07764965 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 22, 2003First studies: 2 phase 2 studiesNew to PfizerPfizer · NCT00074867, NCT00074854
- Dec 20, 2013PanOptica's first study: phase 1 study in Macular DegenerationNew to PanOpticaPanOptica · NCT02022540 · 50 enrolled · United States
- Jun 13, 2015Phase 1 study in Diabetic RetinopathyPanOptica · NCT02475109 · 10 enrolled · United States
- Mar 14, 2018Phase 2 study in Macular DegenerationPanOptica · NCT03479372 · 51 enrolled · United States, Czechia, Hungary and more
- Jun 22, 2026Zhaoke (Guangzhou) Ophthalmology Pharmaceutical's first study: phase 1 study in Macular DegenerationNew to Zhaoke (Guangzhou) Ophthalmology PharmaceuticalZhaoke (Guangzhou) Ophthalmology Pharmaceutical · NCT07764965 · 20 planned
Ahead
- Dec 30, 2026Primary completion: phase 1 study in Macular DegenerationZhaoke (Guangzhou) Ophthalmology Pharmaceutical · NCT07764965
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Ramucirumabrule | Eli Lilly | phase 3 | 58 |
| apatinibrule | Jiangsu HengRui Medicine | phase 3 | 47 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| vorolanibrule | Betta Pharmaceuticals | phase 3 | 24 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07764965Macular Degeneration | 1 | Not yet recruiting | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | Dec 30, 2026 | 20 |
| NCT03479372Macular Degeneration · United States, Czechia, Hungary and more | 2 | Completed | PanOptica | May 27, 2019 | 51 |
| NCT02475109Diabetic Retinopathy · United States | 1 | Completed | PanOptica | May 2016 | 10 |
| NCT02022540Macular Degeneration · United States | 1 | Completed | PanOptica | Mar 2016 | 50 |
| NCT00074867Ovarian Neoplasms · United States, Canada | 2 | Completed | Pfizer | 29 | |
| NCT00074854Lung Neoplasms · United States | 2 | Completed | Pfizer | 87 |
How it is read
Names in the registry
- “PAN-90806 Ophthalmic Solution”, 3 entries
- “CP-547,632”, 2 entries
- “PAN-90806 Ophthalmic Suspension”, 1 entry
Conditions, from the studies’ own filings
- Macular Degeneration, 3 studies
- Diabetic Retinopathy, 1 study
- Lung Neoplasms, 1 study
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.